For example, genetic lesions that enhance PI3K signaling facilitate resistance to imatinib in CML [22], and activation of MAPK has also been implicated in resistance to SMO inhibitors in BCC patients and a mouse model of SHH medulloblastoma [23]. The gene discussed is SMO; the disease is skin basal cell carcinoma.